On August 2, 2017 Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, reported three abstracts were selected for presentation at the third annual CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference (CIMT) (Free CIMT Whitepaper): Translating Science into Survival (Press release, Advaxis, AUG 2, 2017, View Source [SID1234519986]). The prestigious program brings together leading stakeholders in the field to teach, learn and disseminate the latest cutting-edge information and research in cancer immunology and immunotherapy. Schedule your 30 min Free 1stOncology Demo! Two poster presentations will feature preliminary immune correlative data from the ADXS-PSA monotherapy treatment arm of Advaxis’ Phase 1/2 study in combination with KEYTRUDA (pembrolizumab) in metastatic castration-resistant prostate cancer (mCRPC) patients. The third presentation will feature preclinical data with the company’s HPV-targeted immunotherapy, axalimogene filolisbac.
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The poster presentation, "Gene expression profiles associated with stable disease in metastatic castration-resistant prostate cancer patients treated with ADXS-PSA immunotherapy," will feature preliminary data identifying potential pharmacodynamic biomarkers of clinical response in mCRPC patients treated with ADXS-PSA monotherapy.
The second poster presentation, "Persistence of expanded TCRβ clonotypes is associated with clinical activity of ADXS-PSA immunotherapy in metastatic castration-resistant prostate cancer," will focus on the stability of expanded T cell clones in mCRPC patients following treatment with ADXS-PSA monotherapy. The preliminary immune correlative data will be presented by Sandy Hayes, Ph.D., Senior Director of Research and Biomarker Lead at Advaxis.
The third poster presentation, "Identification of an intratumoral immune gene signature associated with tumor regression in an axalimogene filolisbac-treated murine HPV+ tumor model," will include preclinical data regarding molecular biomarkers associated with tumor regression in a murine HPV+ tumor model. It will be presented by Rachelle Kosoff, Ph.D., Senior Scientist in Research at Advaxis.
"Our findings provide important insights into identifying those patients who are benefiting from these treatments," said Dr. Hayes. "We’re pleased to share our findings with the rest of the community at the International Cancer Immunotherapy Conference (CIMT) (Free CIMT Whitepaper) as we continue our work to bring new treatment options to patients."
The third annual International Cancer Immunotherapy Conference (CIMT) (Free CIMT Whitepaper) takes place in the city of Mainz near Frankfurt, Germany from Sept. 6 – 9, 2017, and is jointly sponsored by the Cancer Research Institute (CRI), the Association for Cancer Immunotherapy (CIMT) (Free CIMT Whitepaper), the European Academy of Tumor Immunology (EATI) and the American Association for Cancer Research (AACR) (Free AACR Whitepaper). Presentations will cover all areas of inquiry in cancer immunology and immunotherapy, including: neoantigens and vaccines, novel mechanisms of immunosuppression and immune evasion, biomarkers, new checkpoint immunotherapies and the tumor microenvironment.
To learn more about Advaxis and its immunotherapy clinical programs, visit www.advaxis.com/clinical-trials.